Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2

被引：49
作者：
Huang, Baoying [1 ]
Dai, Lianpan [2 ]
Wang, Hui [3 ]
Hu, Zhongyu [4 ]
Yang, Xiaoming [3 ]
Tan, Wenjie [1 ]
Gao, George F. [2 ]
机构：
[1] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, NHC Key Lab Biosafety, Beijing, Peoples R China
[2] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China
[3] Beijing Inst Biol Prod Co Ltd, Beijing 100176, Peoples R China
[4] Natl Inst Food & Drug Control, Beijing, Peoples R China
来源：
LANCET MICROBE | 2021年 / 2卷 / 07期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/S2666-5247(21)00082-3
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：E285 / E285
页数：1
相关论文
共 5 条
[1]   A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS [J].
Dai, Lianpan ;
Zheng, Tianyi ;
Xu, Kun ;
Han, Yuxuan ;
Xu, Lili ;
Huang, Enqi ;
An, Yaling ;
Cheng, Yingjie ;
Li, Shihua ;
Liu, Mei ;
Yang, Mi ;
Li, Yan ;
Cheng, Huijun ;
Yuan, Yuan ;
Zhang, Wei ;
Ke, Changwen ;
Wong, Gary ;
Qi, Jianxun ;
Qin, Chuan ;
Yan, Jinghua ;
Gao, George F. .
CELL, 2020, 182 (03) :722-+
[2]  
Meng J, 2021, CHINA CDC WEEKLY, V3, P28
[3]   Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine [J].
Wu, Kai ;
Werner, Anne P. ;
Edwards, Darin K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1468-1470
[4]   Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial [J].
Xia, Shengli ;
Zhang, Yuntao ;
Wang, Yanxia ;
Wang, Hui ;
Yang, Yunkai ;
Gao, George Fu ;
Tan, Wenjie ;
Wu, Guizhen ;
Xu, Miao ;
Lou, Zhiyong ;
Huang, Weijin ;
Xu, Wenbo ;
Huang, Baoying ;
Wang, Huijuan ;
Wang, Wei ;
Zhang, Wei ;
Li, Na ;
Xie, Zhiqiang ;
Ding, Ling ;
You, Wangyang ;
Zhao, Yuxiu ;
Yang, Xuqin ;
Liu, Yang ;
Wang, Qian ;
Huang, Lili ;
Yang, Yongli ;
Xu, Guangxue ;
Luo, Bojian ;
Wang, Wenling ;
Liu, Peipei ;
Guo, Wanshen ;
Yang, Xiaoming .
LANCET INFECTIOUS DISEASES, 2021, 21 (01) :39-51
[5]   Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials [J].
Yang, Shilong ;
Li, Yan ;
Dai, Lianpan ;
Wang, Jianfeng ;
He, Peng ;
Li, Changgui ;
Fang, Xin ;
Wang, Chenfei ;
Zhao, Xiang ;
Huang, Enqi ;
Wu, Changwei ;
Zhong, Zaixin ;
Wang, Fengze ;
Duan, Xiaomin ;
Tian, Siyu ;
Wu, Lili ;
Liu, Yan ;
Luo, Yi ;
Chen, Zhihai ;
Li, Fangjun ;
Li, Junhua ;
Yu, Xian ;
Ren, Hong ;
Liu, Lihong ;
Meng, Shufang ;
Yan, Jinghua ;
Hu, Zhongyu ;
Gao, Lidong ;
Gao, George F. .
LANCET INFECTIOUS DISEASES, 2021, 21 (08) :1107-1119
1